MX2018009247A - Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias. - Google Patents
Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias.Info
- Publication number
- MX2018009247A MX2018009247A MX2018009247A MX2018009247A MX2018009247A MX 2018009247 A MX2018009247 A MX 2018009247A MX 2018009247 A MX2018009247 A MX 2018009247A MX 2018009247 A MX2018009247 A MX 2018009247A MX 2018009247 A MX2018009247 A MX 2018009247A
- Authority
- MX
- Mexico
- Prior art keywords
- immunotherapies
- histone deacetylase
- enhancing
- deacetylase inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describen composiciones que incluyen combinaciones de inhibidores de histona desacetilasa (HDAC) de clase I e inhibidores de proteína de muerte celular programada (PD-1) para mejorar la actividad antiumor. Además se describen métodos para administrar estas composiciones como inmunoterapias para suprimir células T reguladoras en el carcinoma de célula renal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662288121P | 2016-01-28 | 2016-01-28 | |
PCT/US2017/015389 WO2017132536A1 (en) | 2016-01-28 | 2017-01-27 | Use of histone deacetylase inhibitors for enhancing immunotherapies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018009247A true MX2018009247A (es) | 2019-03-11 |
Family
ID=58010402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018009247A MX2018009247A (es) | 2016-01-28 | 2017-01-27 | Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias. |
Country Status (13)
Country | Link |
---|---|
US (1) | US10813919B2 (es) |
EP (1) | EP3407913A1 (es) |
JP (1) | JP2019503386A (es) |
KR (1) | KR20180104122A (es) |
CN (1) | CN108883179A (es) |
AU (1) | AU2017211383A1 (es) |
BR (1) | BR112018015291A2 (es) |
CA (1) | CA3013047A1 (es) |
IL (1) | IL260765A (es) |
MX (1) | MX2018009247A (es) |
RU (1) | RU2018130831A (es) |
WO (1) | WO2017132536A1 (es) |
ZA (1) | ZA201805066B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102434314B1 (ko) | 2015-09-01 | 2022-08-19 | 아게누스 인코포레이티드 | 항-pd-1 항체 및 이를 이용하는 방법 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
JP7348074B2 (ja) * | 2017-06-04 | 2023-09-20 | ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズ | がん治療に対する個別化応答の予測方法およびそのキット |
SG10201900072VA (en) * | 2018-01-05 | 2019-08-27 | Gnt Biotech & Medicals Corp | A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy |
JP2021511293A (ja) * | 2018-01-12 | 2021-05-06 | ビラクタ セラピューティクス,インク. | 細胞免疫療法で使用されるエピジェネティック修飾因子 |
KR20210028339A (ko) * | 2019-09-04 | 2021-03-12 | 크리스탈지노믹스(주) | Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물 |
CN112569360A (zh) * | 2019-09-30 | 2021-03-30 | 中国医学科学院药物研究所 | 一种基于阻断pd-1/pd-l1的抗肿瘤药物组合物及其应用 |
WO2023017525A1 (en) | 2021-08-11 | 2023-02-16 | OncoHost Ltd. | Predicting patient response |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ578650A (en) | 2006-12-27 | 2011-12-22 | Harvard College | Pd-1 and activated t-cell compositions and methods for the treatment of viral infections and tumors |
US9987258B2 (en) * | 2014-04-06 | 2018-06-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Histone deacetylase as a modulator of PDL1 expression and activity |
BR112017020002A2 (pt) | 2015-03-20 | 2018-06-19 | Syndax Pharmaceuticals Inc | Combinação de inibidor de hdac e anticorpo anti- pd-1 para o tratamento de câncer |
WO2017035453A1 (en) * | 2015-08-26 | 2017-03-02 | The Johns Hopkins University | Compositions and methods for treating solid tumors |
EP3345002A4 (en) * | 2015-09-02 | 2019-05-08 | Syndax Pharmaceuticals Inc. | SELECTION OF PATIENTS FOR POLYTHERAPY |
-
2017
- 2017-01-27 EP EP17704370.0A patent/EP3407913A1/en not_active Withdrawn
- 2017-01-27 BR BR112018015291A patent/BR112018015291A2/pt not_active IP Right Cessation
- 2017-01-27 KR KR1020187024674A patent/KR20180104122A/ko unknown
- 2017-01-27 AU AU2017211383A patent/AU2017211383A1/en not_active Abandoned
- 2017-01-27 CA CA3013047A patent/CA3013047A1/en not_active Abandoned
- 2017-01-27 RU RU2018130831A patent/RU2018130831A/ru not_active Application Discontinuation
- 2017-01-27 WO PCT/US2017/015389 patent/WO2017132536A1/en active Application Filing
- 2017-01-27 US US16/072,659 patent/US10813919B2/en active Active
- 2017-01-27 JP JP2018539087A patent/JP2019503386A/ja active Pending
- 2017-01-27 MX MX2018009247A patent/MX2018009247A/es unknown
- 2017-01-27 CN CN201780020460.2A patent/CN108883179A/zh active Pending
-
2018
- 2018-07-24 IL IL260765A patent/IL260765A/en unknown
- 2018-07-27 ZA ZA2018/05066A patent/ZA201805066B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3013047A1 (en) | 2017-08-03 |
RU2018130831A (ru) | 2020-03-02 |
WO2017132536A1 (en) | 2017-08-03 |
US10813919B2 (en) | 2020-10-27 |
IL260765A (en) | 2018-10-31 |
EP3407913A1 (en) | 2018-12-05 |
CN108883179A (zh) | 2018-11-23 |
KR20180104122A (ko) | 2018-09-19 |
RU2018130831A3 (es) | 2020-04-23 |
AU2017211383A1 (en) | 2018-08-16 |
BR112018015291A2 (pt) | 2018-12-18 |
US20190030011A1 (en) | 2019-01-31 |
JP2019503386A (ja) | 2019-02-07 |
ZA201805066B (en) | 2019-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018009247A (es) | Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias. | |
PH12020550622A1 (en) | Kras g12c inhibitors | |
MX2022002465A (es) | Inhibidores de kras g12d. | |
MX2020005477A (es) | Inmunoterapias con el uso de células efectoras potenciadas derivadas de ipsc. | |
CY1123676T1 (el) | Συνθεσεις και μεθοδοι για την εσωτερικοποιηση ενζυμων | |
PH12020551881A1 (en) | Mcl-1 inhibitors | |
PH12019501396A1 (en) | Compositions and methods for inhibiting arginase activity | |
MX2018013983A (es) | Inhibidores g12c de kras. | |
EA201790968A1 (ru) | Опосредуемая пептидом доставка направляемой рнк эндонуклеазы в клетки | |
EA201890278A1 (ru) | Антитела к pd-l1 | |
MX2021000299A (es) | Preparados combinados para el tratamiento contra el cancer o infecciones. | |
MX2016007801A (es) | Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa. | |
MX2021006194A (es) | Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc. | |
MX2019001011A (es) | Compuestos farmaceuticos. | |
EA201690027A1 (ru) | Ингибиторы ido | |
EA201592103A3 (ru) | Способы и композиции для усиления cd4+ регуляторных t-клеток | |
MX2017014299A (es) | Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos. | |
PH12018500869A1 (en) | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment | |
BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
PH12019501261A1 (en) | Heterocyclic inhibitors of mct4 | |
SA519410093B1 (ar) | مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز | |
EA201591752A1 (ru) | Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы | |
MX2022006304A (es) | Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles. | |
MX2017011018A (es) | Inhibicion de la actividad de olig2. | |
ZA201901367B (en) | Inhibition of olig2 activity |